Immutep (Immutep) Price-to-Tangible-Book : 4.32 (As of Apr. 25, 2024)

View and export this data going back to 1988. Start your Free Trial

What is Immutep Price-to-Tangible-Book?

As of today (2024-04-25), Immutep's share price is $2.60. Immutep's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.60. Hence, Immutep's Price to Tangible Book Ratio of today is 4.32.

The historical rank and industry rank for Immutep's Price-to-Tangible-Book or its related term are showing as below:

IMMP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.19 Med: 5.88 Max: 56
Current: 5

During the past 13 years, Immutep's highest Price to Tangible Book Ratio was 56.00. The lowest was 2.19. And the median was 5.88.

IMMP's Price-to-Tangible-Book is ranked worse than
72.87% of 1220 companies
in the Biotechnology industry
Industry Median: 2.67 vs IMMP: 5.00

A closely related ratio is called PB Ratio. As of today, Immutep's share price is $2.60. Immutep's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.65. Hence, Immutep's P/B Ratio of today is 3.99.

Immutep Price-to-Tangible-Book Historical Data

The historical data trend for Immutep's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Price-to-Tangible-Book Chart

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Price-to-Tangible-Book

Get a 7-Day Free Trial

12.21

4.29

6.37

3.04

2.94

Immutep Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															3.47	-	2.94	-	3.99

Competitive Comparison of Immutep's Price-to-Tangible-Book

For the Biotechnology subindustry, Immutep's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immutep's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Immutep's Price-to-Tangible-Book falls into.

Immutep Price-to-Tangible-Book Calculation

Immutep's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	2.60	/	0.602
	=	4.32

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Immutep Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Immutep's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep (Immutep) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (NAS:IMMP) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

PRRUF:USA YP1B:Germany IMM:Australia

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.